Validated LC-MS/MS method for simultaneous determination of doxorubicin and curcumin in polymeric micelles in subcellular compartments of MCF-7/Adr cells by protein precipitation-ultrasonic breaking method

2016 ◽  
Vol 31 (6) ◽  
pp. e3892 ◽  
Author(s):  
Jinling Wang ◽  
Ying Li ◽  
Wenzhuan Ma ◽  
Xiaohui Wang ◽  
Pengfei Tu
Keyword(s):  
Simultaneous Determination ◽  
Polymeric Micelles ◽  
Protein Precipitation ◽  
Subcellular Compartments ◽  
Mcf 7

Simultaneous Determination of Ritonavir and Lopinavir in Human Plasma after Protein Precipitation and LC-MS-MS

2010 ◽  
Vol 71 (9-10) ◽  
pp. 815-824 ◽  
Author(s):  
Rajasekhar Damaramadugu ◽  
Jaswanthkumar Inamadugu ◽  
Ravi Kanneti ◽  
Srinivasulu Polagani ◽  
Venkateswarlu Ponneri
Keyword(s):  
Simultaneous Determination ◽  
Human Plasma ◽  
Protein Precipitation

scholarly journals Development and Validation of Valganciclovir and its Active Metabolite Ganciclovir Determination in Human Plasma by HPLC-UV Method

2020 ◽  
Vol 9 (2) ◽  
pp. 133-139
Author(s):  
T. N. Komarov ◽  
I. E. Shohin ◽  
O. A. Miskiv ◽  
D. S. Bogdanova ◽  
A. V. Aleshina ◽  
...  
Keyword(s):  
Quantitative Determination ◽  
Simultaneous Determination ◽  
Human Plasma ◽  
Active Metabolite ◽  
Protein Precipitation ◽  
Human Blood Plasma ◽  
Pharmacokinetic Studies ◽  
Validation Parameters ◽  
Development And Validation

Introduction. Viral infections are a serious problem that occurs during the use of immunosuppressants in preparation for organ transplantation and in the postoperative period. Cytomegalovirus (CMV) infection is one of the main causes of diseases in people with weakened immune systems. It has a direct impact on one’s body and makes it more likely to reject a transplanted organ. Antiviral drugs are used to treat and prevent this infectious disease. Valganciclovir is a prodrug whose active metabolite is ganciclovir. Valganciclovir is the drug of choice in the treatment of CMV infections. Currently, there are no researches on the matter of simultaneous determination of both valganciclovir and ganciclovir in human blood plasma by means of high-performance liquid chromatography (HPLC) with ultraviolet detection. This research delivers a thorough description of development and validation of a particular method for simultaneous determination of valganciclovir and ganciclovir in the plasma after sample preparation by the method of protein precipitation.Aim. The aim of this study is to develop method for the quantitative determination of valganciclovir and its active metabolite ganciclovir in human plasma by HPLC-UV for pharmacokinetic studies.Materials and methods. Quantitative determination of tadalafil in plasma by HPLC-UV. A sample was prepared using protein precipitation.Results and discussion. This method was validated by next validation parameters: selectivity, matrix effect, calibration curve, accuracy, precision, lower limit of quantification, carry-over and stability.Conclusion. The method of the quantitative determination of valganciclovir and its active metabolite ganciclovir in human plasma was developed and validated by HPLC-UV. The analytical range of the was 5,0–1000,0 ng/ml for valganciclovir and 100,0–10000,0 ng/ml for ganciclovir in plasma. Method could be applied to determination of valganciclovir and ganciclovir in plasma for PK and BE studies.

Simultaneous Determination of Alogliptin and Pioglitazone in Human Plasma by a Novel LC-MS/MS Method

2020 ◽  
Vol 16 (5) ◽  
pp. 564-577
Author(s):  
Duddukuru Sri Sesha Sai Praveen ◽  
Syed Asha ◽  
Ravi Kumar Pigili
Keyword(s):  
Simultaneous Determination ◽  
Human Plasma ◽  
Solid Phase ◽  
Protein Precipitation ◽  
Detection Methods ◽  
Therapeutic Drug ◽  
Internal Standards ◽  
One Step ◽  
Precision And Accuracy

Background: A combination of alogliptin and pioglitazone is well tolerated. It does not increase the risk of hypoglycemia. In order to study the bioavailability of aloglipitn in the presence of pioglitazone, it is essential to have a method that can simultaneously detect both in human plasma. A protein precipitation-based method was used to determine alogliptin and pioglitazone simultaneously in human plasma. Protein precipitation causes ion suppression or enhancement in detection methods when compared to other methods. Objective: To simultaneously quantify alogliptin and pioglitazone in human plasma by LC-MS/MS based method. Methods: LC-MS/MS method for the simultaneous determination of pioglitazone and alogliptin in human plasma using stable isotope labelled compounds internal standards. The simple and one step solid phase extraction (SPE) was employed to extract the analytes from plasma. The extracted samples were separated on a C18 column by using a 25:75 (v/v) mixture of acetonitrile and 5 mM ammonium formate as the mobile phase at a flow rate of 0.5 mL/min. Results: The calibration curves obtained were linear (r2= 0.99) over the concentration range of 12.0- 2438.0 ng/mL for pioglitazone and 1.0-202.0 ng/mL for alogliptin. The results of the intra- and interday precision and accuracy studies were found to be within the acceptable limits. The analytes were stable under different stability conditions. All the validation results were found to be within the acceptable limits. The total analytical run time was 3.0 min. There was no interference from plasma matrices. Conclusion: The developed method is precise and adequately sensitive for detection and quantification of analytes. Thus, the method can be useful for bioavailability and bioequivalence (BA/BE) studies and routine therapeutic drug monitoring with the desired precision and accuracy.

A quantitative LC-MS/MS Method for the Simultaneous Determination of the Presence of R-α-lipoic acid and S-α-lipoic acid after Protein Precipitation in rat Plasma and its Application in a Toxicokinetic Study

2020 ◽  
Vol 17 ◽  
Author(s):  
Wenjun Zhou ◽  
Hongqun Qiao ◽  
Lingling Xu ◽  
Yanjuan Yuan ◽  
Qing Shao
Keyword(s):  
Gender Differences ◽  
Simultaneous Determination ◽  
Lipoic Acid ◽  
Water Soluble ◽  
Protein Precipitation ◽  
Plasma Samples ◽  
Ionization Source ◽  
Toxicological Studies

Background: Lipoic acid is the only known chiral antioxidant that is both lipid-soluble and water-soluble. It is often used as a treatment for peripheral polyneuropathy caused by diabetes, alcohol, and chemicals. However, only a few long-term toxicological studies have been conducted on R-α-lipoic acid, which is a bioactive ingredient in lipoic acid. Objective: In this study, a simple, efficient, sensitive and stable LC-MS/MS method was used to determine RLA in rats, using deu-lipoic acid as an internal standard. Method: The samples to be detected were plasma samples treated with protein precipitation and the simultaneous determination of the presence of R-α-lipoic acid and S-α-lipoic acid was conducted using LC-MS/MS. An isocratic elution program with a mobile phase composed of acetonitrile and 0.1% formic acid water solution (52/48) used for chromatographic separation was set up using a CHIRALPAK® IE C18 (250 mm × 4.6 mm, 5 μm) column with a flow rate of 0.9 mL/min. A negative electrospray ionization source was chosen and the multiple monitoring (MRM) mode was applied. Results: R-α-lipoic acid and S-α-lipoic acid both were found to be present at a linear range of 5-5000 ng/mL. The plasma samples were stable under various storage conditions and temperatures. The toxicokinetics study indicated that there were gender differences and that R-α-lipoic acid showed bioaccumulative toxicity after long-term daily administration. In addition, R-α-lipoic acid and S-α-lipoic acid were not converted into each other in the rats. Conclusions: The method established was successfully used for the long-term toxicokinetic study of R-α-lipoic acid administered to rats through caudal vein injection. The toxicokinetics results indicated the presence of gender differences and the toxic accumulation of R-α-lipoic acid. The two enantiomers were not converted into each other in the rats.

Sign in / Sign up

Export Citation Format

Share Document